Prolactin, 19-nors and the test nobody takes

What a 19-nor is, plus what progestogenic actually means Mixed

A 19-nor compound is a steroid missing the carbon-19 methyl group that testosterone carries. Nandrolone is the parent of the group. Trenbolone is a 19-nor as well. Removing that carbon changes how the molecule sits in several receptors at once, which is why these compounds behave differently from testosterone derivatives in ways that have nothing to do with potency.

The specific difference people mean by progestogenic is affinity for the progesterone receptor. Nandrolone's is genuinely higher than testosterone's, reported across assays in the region of five to twenty times. That sounds decisive until you see the other comparison: nandrolone's affinity for the progesterone receptor is under a fifth of progesterone's own, or of a real progestin like norethisterone. Both figures vary by preparation and assay, which is part of why this effect is easier to name than to quantify. So the effect is real in relative terms and weak in absolute terms, partly offset by the fact that these compounds are used at doses far larger than a progestin ever would be.

It is also messier than a single number suggests. Classic receptor work on 19-nortestosterone derivatives found, binding to the rabbit uterine progesterone receptor, that several of them behave as antagonists or as mixed agonist-antagonists rather than as clean agonists. Which behavior dominates depends on the compound, the tissue plus the surrounding hormonal environment. Anyone describing this group as simply progestogenic has flattened something that the underlying pharmacology does not flatten.

Progestogenic activity is not the same as high prolactin Mixed

Here is the conflation that drives most of the confusion, plus most of the unnecessary medication.

Progesterone-receptor activity in breast tissue is one mechanism. It can plausibly sensitize that tissue to circulating estrogen, which is the usual explanation offered for gynecomastia developing on a 19-nor while estradiol looks unremarkable on paper. Progesterone receptors are found in gynecomastia tissue, though the mechanism in men is inferred more than it is measured. Serum prolactin is a completely separate measurement, produced by the anterior pituitary under dopamine control. The two are related in the literature, they are not interchangeable, plus one of them is a blood test you can order for very little money.

What happens in practice is that someone on nandrolone notices sore or puffy nipples, reads that 19-nors raise prolactin, concludes they have prolactin gynecomastia then starts a dopamine agonist. Prolactin was never measured. It might have been normal. The symptom might have been estrogenic rather than progestogenic. The drug they reached for treats one specific cause of one specific presentation, so if that cause was absent it can only do harm.

The general workup for a genuinely raised prolactin, including the macroprolactin trap plus the draw conditions that produce false highs, is covered on prolactin in men. That page is worth reading before this one becomes actionable, because a wrong number leads to a wrong drug just as reliably as no number does.

Nandrolone and trenbolone are not equally evidenced Mixed

They get named together in every discussion of this topic. The evidence behind them is not equivalent.

Nandrolone's progesterone-receptor affinity is documented in the pharmacology literature, plus its clinical use history is long enough that the progestogenic effects have been observed rather than inferred. Trenbolone is the one where the claim outruns the data. It is a 19-nor, it does not aromatize, plus it has recognized progestogenic character. What is largely missing is human measurement showing it reliably raises serum prolactin. Most of the confident statements about trenbolone and prolactin trace to forum consensus rather than to a study.

That does not make the concern baseless. It makes it a hypothesis worth testing on yourself with a blood test rather than a certainty worth medicating blind. It also explains a common experience: people who take a dopamine agonist for trenbolone-related symptoms often report nothing changed, which is what you would expect if prolactin was not the mechanism.

Cabergoline versus pramipexole Strong evidence

Both are dopamine agonists. They are not equivalent choices.

Cabergoline is a long-acting D2 agonist approved specifically for hyperprolactinemic disorders. Its evidence base in this indication is substantial, it is the drug endocrine guidelines actually reach for, plus its dosing in hyperprolactinemia is measured in fractions of a milligram once or twice a week rather than daily.

Pramipexole is a dopamine agonist licensed for Parkinson's disease plus restless legs syndrome. It lowers prolactin, because dopamine agonists do. It has no approved indication in hyperprolactinemia plus it is dosed daily. Choosing it over cabergoline is choosing the drug with less evidence in the condition being treated.

Impulse-control problems belong to both. Hypersexuality, binge eating, compulsive spending or gambling are a class effect of dopamine agonists rather than a pramipexole quirk. They are documented in cabergoline-treated hyperprolactinemia at rates reported between roughly 8 and 46% depending on the series. Pramipexole's disadvantage is the absence of evidence in this condition, not a monopoly on that side effect.

The valve question deserves precision rather than either reassurance or alarm. Ergot-derived dopamine agonists at the high daily doses used in Parkinson's disease are established causes of cardiac valvulopathy. That is not in dispute. The question is whether the far smaller doses used for hyperprolactinemia carry the same risk, which a 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism addressed directly. Pooling 13 case-control studies of patients treated for at least six months, it found more tricuspid regurgitation in cabergoline-treated patients than controls, with an odds ratio of 3.74. Two qualifications carry as much weight as the finding: no patient had tricuspid valve dysfunction diagnosed on the basis of clinical symptoms, plus there was no significant increase in any other valvulopathy. So within those studies the signal is echocardiographic and confined to one valve.

That is not the same as harmless, so stopping there would be dishonest. Symptomatic cabergoline-associated tricuspid valvulopathy is documented in prolactinoma patients, including a fatal case, at cumulative doses larger and longer than the surveillance studies covered. Which is precisely the exposure a person dosing themselves indefinitely is in. Worth adding that echocardiographic screening is a regulatory requirement of cabergoline prescribing, so the monitoring that makes this risk manageable is exactly what someone self-sourcing does not get.

Read honestly, that is neither nothing nor a reason for panic. It is an argument against standing prophylaxis, plus for any use being the smallest amount a clinician judges necessary against a measured problem, over a defined period, with the echocardiographic monitoring that comes with a prescription.

Three things that move this out of self-management Strong evidence

Breast tissue that is firm, one-sided or growing needs examining rather than medicating. Not every cause is hormonal, the list includes testicular plus hCG-secreting tumors and thyroid disease. Once the tissue is fibrotic it does not respond to any drug on this page.

New or worsening headache, or any change in peripheral vision, alongside a raised prolactin is a pituitary question that warrants imaging rather than a dopamine agonist.

New compulsive behavior on any dopamine agonist, meaning gambling, spending, hypersexuality or binge eating, is a recognized drug effect that the person affected usually does not notice first. It needs the drug stopped plus a clinician involved.

What the calculator flags, plus what it cannot Strong evidence

The cycle calculator marks a 19-nor in the stack, because that is a structural fact about the molecule you selected. It also flags the interaction that catches people out in the other direction: a 5-alpha reductase inhibitor running alongside a 19-nor. With testosterone, 5-alpha reduction produces the more potent DHT, so blocking it lowers androgenic load. With nandrolone the same enzyme produces dihydronandrolone, which is weaker, so blocking it leaves more of the stronger parent compound in play. The intervention people use to protect their hairline does something close to the opposite here.

What no calculator can tell you is your prolactin. That is a blood test, it is inexpensive, plus it is the only thing on this page that turns a guess into a decision.